Deutsche Bank
NBSE

Deutsche Bank’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Deutsche Bank’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,000
Closed -$105K – 4107
2022
Q2 		$105K Hold
5,000
– – ﹤0.01% 3501
2022
Q1 		$188K Hold
5,000
– – ﹤0.01% 3308
2021
Q4 		$281K Hold
5,000
– – ﹤0.01% 3193
2021
Q3 		$361K Hold
5,000
– – ﹤0.01% 3239
2021
Q2 		$479K Buy
5,000
+4,415
+755% +$488K ﹤0.01% 3253
2021
Q1 		$86K Sell
585
-51
-8% -$9.24K ﹤0.01% 4058
2020
Q4 		$89K Buy
636
+149
+31% +$24.1K ﹤0.01% 3908
2020
Q3 		$74K Buy
487
+42
+9% +$6.85K ﹤0.01% 3690
2020
Q2 		$78K Buy
+445
New +$74.5K ﹤0.01% 3580
2020
Q1 		– Sell
-271
Closed -$38K – 4944
2019
Q4 		$38K Buy
+271
New +$31.8K ﹤0.01% 4079
2018
Q1 		– Sell
-50
Closed -$37K – 5651
2017
Q4 		$37K Hold
50
– – ﹤0.01% 4541
2017
Q3 		$14K Hold
50
– – ﹤0.01% 4621
2017
Q2 		$12K Hold
50
– – ﹤0.01% 4647
2017
Q1 		$16K Hold
50
– – ﹤0.01% 4556
2016
Q4 		$29K Hold
50
– – ﹤0.01% 4504
2016
Q3 		$56K Sell
50
-5
-9% -$5.39K ﹤0.01% 4176
2016
Q2 		$59K Sell
55
-238
-81% -$299K ﹤0.01% 4344
2016
Q1 		$375K Sell
293
-179
-38% -$255K ﹤0.01% 3367
2015
Q4 		$1.16M Buy
472
+417
+758% +$640K ﹤0.01% 2779
2015
Q3 		$60K Sell
55
-11
-17% -$12.7K ﹤0.01% 4354
2015
Q2 		$66K Buy
66
+6
+10% +$6.47K ﹤0.01% 4459
2015
Q1 		$60K Sell
60
-74
-55% -$244K ﹤0.01% 4328
2014
Q4 		$445K Buy
134
+4
+3% +$12.3K ﹤0.01% 3754
2014
Q3 		$377K Buy
130
+125
+2,500% +$413K ﹤0.01% 3683
2014
Q2 		$19K Sell
5
-6
-55% -$22.6K ﹤0.01% 5333
2014
Q1 		$59K Buy
11
+7
+175% +$36.9K ﹤0.01% 4475
2013
Q4 		$11K Sell
4
-4
-50% -$12.3K ﹤0.01% 4876
2013
Q3 		$24K Buy
8
+4
+100% +$10.9K ﹤0.01% 4870
2013
Q2 		$12K Buy
+4
New +$12.9K ﹤0.01% 4883

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Deutsche Bank's NBSE Position: Q3 2022 in Review

Deutsche Bank sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2022, closing a stake of 5,000 shares — an estimated $105K sold.

Deutsche Bank first reported a position in NBSE in Q2 2013 and held it in 29 quarters. The position peaked at $1.16M in Q4 2015. 44 funds tracked by Wall St. Rank hold NBSE as of Q3 2022.

  • Deutsche Bank reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Deutsche Bank sold 5,000 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $105K.
  • Deutsche Bank first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2013 and held it in 29 quarters.
  • Deutsche Bank's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.16M in Q4 2015.
  • 44 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Deutsche Bank's 13F filing for Q3 2022, filed 14 Nov 2022.